Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

(2009) G. Lopez et al.   CLINICAL CANCER RESEARCH

Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45α expression

(2008) Cao Yang et al.   APOPTOSIS

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

Histone deacetylase inhibitors: Anticancer compounds

(2008) Karen T. Smith et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist

(2008) L. E. Tavera-Mendoza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA